Two Sigma Advisers LP lifted its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 2.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,043,580 shares of the insurance provider's stock after buying an additional 24,500 shares during the period. Two Sigma Advisers LP owned approximately 0.87% of Humana worth $330,544,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. PDT Partners LLC increased its stake in Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider's stock worth $1,286,000 after acquiring an additional 2,660 shares during the last quarter. Ontario Teachers Pension Plan Board increased its position in Humana by 6.5% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider's stock worth $371,705,000 after purchasing an additional 71,910 shares in the last quarter. Swedbank AB raised its holdings in Humana by 3.0% in the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider's stock valued at $33,567,000 after buying an additional 3,085 shares during the period. Heritage Oak Wealth Advisors LLC acquired a new position in Humana during the second quarter valued at approximately $3,456,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Humana by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 899,191 shares of the insurance provider's stock worth $284,810,000 after buying an additional 26,056 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.
NYSE HUM opened at $283.06 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $498.17. The company has a 50-day simple moving average of $273.44 and a 200-day simple moving average of $327.75. The firm has a market capitalization of $34.08 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 2.29 and a beta of 0.53.
Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities analysts forecast that Humana Inc. will post 15.86 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana's payout ratio is 31.36%.
Several research firms recently weighed in on HUM. Oppenheimer reduced their target price on shares of Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a report on Thursday, October 3rd. KeyCorp assumed coverage on Humana in a research report on Friday, October 11th. They issued a "sector weight" rating for the company. Leerink Partners lowered Humana from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. TD Cowen boosted their price target on Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Finally, Sanford C. Bernstein raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $308.00 price objective for the company in a research report on Tuesday, October 8th. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $315.86.
Get Our Latest Research Report on HUM
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.